FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC Pooled analysis finds correlations between early endpoints and OS in ICI trials

Teclistamab improves outcomes in relapsed MM, phase III trial finds

An international phase III study showed that patients with relapsed multiple myeloma treated with teclistamab lived longer and remained in remission significantly longer than patients receiving standard therapies.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

June 05, 2026

Vol.52 No.22

Clinical Roundup

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

OST-HER2 (OST31-164) achieved statistically significant benefit for treated patients in overall survival at the 2.5-year timepoint in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (75% vs. 47%, p = 0.003).

June 05, 2026

Vol.52 No.22

Drugs & Targets

FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm

FDA approved Decnupaz (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval is supported by data from the phase I/II CADENZA trial, a global study evaluating the safety and efficacy of Decnupaz for BPDCN.

June 05, 2026

Vol.52 No.22

Podcast The Directors

The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight

Getting NCI clinical trials to the community has never been an easy task. Has it been getting simpler or more difficult in recent years?

May 29, 2026

Vol.52 No.21

By Paul Goldberg and Claire Marie Porter

FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC

Pooled analysis finds correlations between early endpoints and OS in ICI trials

YOU MAY BE INTERESTED IN

Teclistamab improves outcomes in relapsed MM, phase III trial finds

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm

The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight

Renew today!

Subscriber content

Never miss an issue!

Login